Sequana Medical Pumped About NASH's Market Potential
Executive Summary
Following a fresh injection of funding, Sequana Medical is gearing up to grow its European business and begin a pivotal US study for alfapump, its implantable, automated pump for the continual removal of ascites. The Belgian company is positioning itself as a key player in the growing liver disease treatment market.
You may also be interested in...
Sequana Medical Secures $21M In Private Placement
One year on from its IPO on Euronext Brussels, abdominal implant maker Sequana Medical has secured €19m ($21m) in an equity placement. The company said it had been backed by new and existing investors.
Sequana Medical Launches Belgian IPO
Sequana Medical has launched an IPO on Euronext Brussels a few days after the US FDA granted a breakthrough device designation to Sequana’s alfapump for liver ascites.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.